Phase I study of UFT plus leucovorin in advanced colorectal cancer: a double modulation proposal

Anticancer Res. 1993 May-Jun;13(3):759-62.

Abstract

Twenty-six patients with advanced colorectal cancer were treated with UFT and leucovorin (LV). On day 1, patients received LV 500 mg/m2 in IV infusion, followed by 15 mg/12 h for 13 days. On days 1 to 14, patients took oral UFT twice daily. Three cycles were given every 28 days, unless grade III-IV toxicity appeared. The initial dose of UFT (200 mg/day) was increased until 800 mg/day. Dose limiting toxicities were stomatitis, diarrhea and epigastralgia. The maximum tolerated dose of UFT was 390 +/- 10 mg/m2. Three out of 24 evaluable patients achieved a partial response and 1 a complete response with UFT doses of 260 to 390 mg/m2. These results warrant confirmation in phase II studies.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I

MeSH terms

  • Administration, Oral
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols*
  • Colonic Neoplasms / drug therapy*
  • Drug Administration Schedule
  • Drug Combinations
  • Female
  • Humans
  • Leucovorin / administration & dosage*
  • Male
  • Middle Aged
  • Rectal Neoplasms / drug therapy*
  • Tegafur / administration & dosage
  • Uracil / administration & dosage

Substances

  • Drug Combinations
  • Tegafur
  • Uracil
  • Leucovorin

Supplementary concepts

  • 1-UFT protocol